Eikon Therapeutics (EIKN) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
YD Bio is the larger company by market cap ($416.5 million vs $394.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | YDES |
|---|---|---|
| Share price | $7.29 | $5.88 |
| Market cap | $394.86M | $416.49M |
| 1-day change | -3.32% | 0.00% |
| YTD return | — | -51.76% |
| 1-year return | — | -67.33% |
| EPS (TTM) | $-8.51 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $22.00 |
| 52-week low | $7.02 | $1.70 |
| Distance from 52-week high | -58.10% | -73.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +237.45% | — |
| Average volume | 492.68K | 283.39K |
| Shares outstanding | 54.17M | 70.83M |
| Employees | 384 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
EIKN vs YDES FAQ
Which is bigger, Eikon Therapeutics or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $416.49M compared with $394.86M for Eikon Therapeutics (EIKN).
Are Eikon Therapeutics and YD Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eikon Therapeutics and Medical Specialities for YD Bio.